164 related articles for article (PubMed ID: 36456600)
1. Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides.
Mansour S; Adhya I; Lebleu C; Dumpati R; Rehan A; Chall S; Dai J; Errasti G; Delacroix T; Chakrabarti R
Sci Rep; 2022 Dec; 12(1):20725. PubMed ID: 36456600
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library.
Denholt CL; Hansen PR; Pedersen N; Poulsen HS; Gillings N; Kjaer A
Biopolymers; 2009 Mar; 91(3):201-6. PubMed ID: 19107925
[TBL] [Abstract][Full Text] [Related]
3. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of a novel human scFv inhibiting EGFR vIII expressing cancers.
Rahbarnia L; Farajnia S; Babaei H; Majidi J; Dariushnejad H; Hosseini MK
Immunol Lett; 2016 Dec; 180():31-38. PubMed ID: 27984065
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
[TBL] [Abstract][Full Text] [Related]
6. Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery.
Furman O; Zaporozhets A; Tobi D; Bazylevich A; Firer MA; Patsenker L; Gellerman G; Lubin BCR
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890400
[TBL] [Abstract][Full Text] [Related]
7. Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma.
McIntyre JB; Bose P; Klimowicz AC; Brockton NT; Petrillo S; Matthews W; Easaw J; Magliocco A; Dort JC
PLoS One; 2012; 7(2):e31723. PubMed ID: 22359620
[TBL] [Abstract][Full Text] [Related]
8. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
9. Development of a Novel Human Single Chain Antibody Against EGFRVIII Antigen by Phage Display Technology.
Rahbarnia L; Farajnia S; Babaei H; Majidi J; Akbari B; Ahdi Khosroshahi S
Adv Pharm Bull; 2016 Dec; 6(4):563-571. PubMed ID: 28101463
[No Abstract] [Full Text] [Related]
10. The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
Kim HM; Lee SH; Lim J; Yoo J; Hwang DY
Cell Prolif; 2021 Feb; 54(2):e12965. PubMed ID: 33283409
[TBL] [Abstract][Full Text] [Related]
11. Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.
Miller ML; Tome-Garcia J; Waluszko A; Sidorenko T; Kumar C; Ye F; Tsankova NM
J Mol Diagn; 2019 May; 21(3):514-524. PubMed ID: 31000415
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.
Denholt CL; Binderup T; Stockhausen MT; Poulsen HS; Spang-Thomsen M; Hansen PR; Gillings N; Kjær A
Nucl Med Biol; 2011 May; 38(4):509-15. PubMed ID: 21531288
[TBL] [Abstract][Full Text] [Related]
13. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
14. The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III.
Xu W; Song F; Wang B; Li K; Tian M; Yu M; Pan X; Shi B; Liu J; Gu J; Li Z; Jiang H
Cell Physiol Biochem; 2018; 46(1):226-237. PubMed ID: 29587298
[TBL] [Abstract][Full Text] [Related]
15. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
[TBL] [Abstract][Full Text] [Related]
16. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
[TBL] [Abstract][Full Text] [Related]
17. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
Lorimer IA; Keppler-Hafkemeyer A; Beers RA; Pegram CN; Bigner DD; Pastan I
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14815-20. PubMed ID: 8962138
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
